Skip to main content

Pura Vida Investments, LLC's Form 4/A amendment

Amended

Insight Molecular Diagnostics Inc. (IMDX) · filed Apr 29, 2022

Accession no.
0001829126-22-009190
Filed
Apr 29, 2022, 4:33 PM ET
Trade date
Apr 14, 2022
Filing delay
15 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Apr 18, 2022

This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market purchases total $7.89M. It was filed 15 days after the trade.

This filing was later replaced by the amendment 0001209191-22-039690 (Jun 28, 2022). Trade tables on this site use the amended version.

This amendment replaces 0001829126-22-008372 (filed Apr 18, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Pura Vida Investments, LLCCIK 000159014410% Owner
Kamen EfremCIK 000178919310% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 14, 2022Common StockPPurchaseAcquired+1,665,898$1.33+$2,219,809.097,350,447Indirect
Apr 14, 2022Common StockPPurchaseAcquired+30,790$1.23+$37,779.337,381,237Indirect
Apr 14, 2022Common StockPPurchaseAcquired+92,370$1.26+$116,386.27,473,607Indirect
Apr 14, 2022Common StockPPurchaseAcquired+1,916,419$1.33+$2,553,628.328,455,823Indirect
Apr 14, 2022Common StockPPurchaseAcquired+19,210$1.23+$23,570.678,475,033Indirect
Apr 14, 2022Common StockPPurchaseAcquired+57,630$1.26+$72,613.88,532,663Indirect
Apr 14, 2022Common StockPPurchaseAcquired+767,952$1.33+$1,023,296.04767,952Indirect
Apr 14, 2022Common StockPPurchaseAcquired+1,381,438$1.33+$1,840,766.141,381,438Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 14, 2022Common StockPPurchaseAcquired+832,949–F1–832,949Indirect
Apr 14, 2022Common StockPPurchaseAcquired+383,976–F1–383,976Indirect
Apr 14, 2022Common StockPPurchaseAcquired+690,719–F1–690,719Indirect
Apr 14, 2022Common StockPPurchaseAcquired+958,209–F1–958,209Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325.

Referenced by the price of 4 transactions in Table II.

F2

Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.

F3

By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.

F4

The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise.

Remarks

This amendment to the Form 4 is being filed solely to correct the address reported for Efrem Kamen.

Read the full filing on SEC EDGAR (opens in a new tab)